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PValvular Heart Disease
ong-Term Survival and Functional
esults After Aortic Valve Replacement in
symptomatic Patients With Chronic Severe
ortic Regurgitation and Left Ventricular Dysfunction
oldano Scognamiglio, MD, Christian Negut, MD, Monica Palisi, MD, Giuseppe Fasoli, MD,
ergio Dalla-Volta, MD
adua, Italy
OBJECTIVES We examined the influence of medical treatment on the results of surgery in terms of
long-term survival and functional results in patients with chronic, severe aortic regurgitation
(AR).
BACKGROUND Asymptomatic patients with AR and a reduced left ventricular ejection fraction (LVEF) are
at high risk because of a higher-than-expected long-term mortality. The influence of
preoperative medical therapy on the outcome after aortic valve replacement (AVR) is not well
known.
METHODS Surgery was indicated for the appearance of a reduced LVEF (50%). At the time of AVR,
there were 134 patients treated with nifedipine (group A), and 132 received no medication
(group B).
RESULTS Operative mortality was similar in the two groups (0.75% vs. 0.76%, p  NS). The LVEF
normalized in all of group A, whereas it remained abnormal in 36 group B patients (28%). At
10-year follow-up, LVEF persisted higher in group A (62  5% vs. 48  4%, p  0.001).
Five-year survival was similar in the two groups (94  2% vs. 94  3%, p  NS). Group A
showed a 10-year survival not different from expected and significantly higher than that in
group B (85  4% vs. 78  5%, p  0.001), which had a worse survival than expected.
CONCLUSIONS Unloading treatment with nifedipine in AR allows one to indicate AVR at the appearance of
a reduced LVEF with a low operative mortality and an optimal long-term outcome. The
concept of surgical correction of AR indicated for reduced LVEF may not be applied to all
patients. Indeed, in a large amount of untreated patients, a reduced LVEF preoperatively is
not reversed by prompt surgery, indicating irreversible myocardial damage, and 10-year
survival is worse than expected. (J Am Coll Cardiol 2005;45:1025–30) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.06.081American College of Cardiology Foundation
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phe decision to recommend operative intervention to the
symptomatic patient with chronic, severe aortic regurgita-
ion (AR) is very difficult because aortic valve replacement
AVR) continues to entail immediate risk, and biologic and
echanical valves still have problems resulting in significant
orbidity and mortality. On the other hand, the mortality
See page 1031
ate in asymptomatic patients with AR is very low, and
urgery does not improve the quality of life. Thus, the
ndication in asymptomatic patients must be delayed until
hanges occur that will predict an increased risk of operative
r long-term death after AVR.
It is not clear whether the occurrence of a reduced left
entricular ejection fraction (LVEF) in asymptomatic patients
ith AR represents the right moment to recommend surgery
From the Division of Cardiology, Department of Clinical and Experimental
edicine, University of Padua Medical School, Padua, Italy.s
Manuscript received April 14, 2004; revised manuscript received June 10, 2004,
ccepted June 22, 2004.r whether this is a parameter that will predict a less-than-
ptimal result. The issue of patients with AR after deteriora-
ion of LVEF has occurred offers an intriguing clinical and
athophysiologic problem. Particularly, controversies exist
bout the questions of whether the risks of surgery are too
igh, and whether any improvement in LVEF and survival can
ealistically be expected after successful AVR. Several studies
upport the idea that asymptomatic patients with normal
VEF should undergo surgery without waiting for the devel-
pment of symptoms or reduced LVEF. This conclusion is
ased on the demonstration that reduced LVEF has a marked
nfluence on survival after aortic valve replacement (1–5).
owever, other studies indicate that there is no reliable
vidence that early valve replacement is beneficial in asymp-
omatic patients with normal LVEF (6–9), and in the absence
f symptoms, the chief indication is the development of
educed LVEF (5,10–15). Recently, a long-term follow-up
tudy (5) showed that asymptomatic patients with normal
VEF had a 10-year mortality rate not different from ex-
ected, whereas those with reduced LVEF constituted a
ubgroup with excess mortality rates with conservative man-
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Survival After AVR April 5, 2005:1025–30gement. The authors concluded that these patients should be
onsidered at high risk and evaluated for prompt intervention.
nfortunately, data on postoperative survival derived from
arge series of these patients are not available. Moreover, the
ffects of medical treatment are largely unknown, because in
hese studies patients received, in variable proportion, calcium
hannel blockers, angiotensin-converting enzyme inhibitors,
ydralazine, beta-blockers, digoxin, or none of these (1–12). In
previous study, unloading therapy with nifedipine in asymp-
omatic patients with normal LVEF delayed surgery (indicated
y the appearance of reduced LVEF), and all patients re-
ponded favorably to aortic valve replacement with normaliza-
ion of the ejection fraction (16).
The present study prospectively assessed operative mor-
ality, long-term survival, and functional results in asymp-
omatic patients who underwent AVR after deterioration of
VEF. The effects of a preoperative unloading therapy with
ifedipine or the absence of medical therapy were also
valuated.
ETHODS
atient selection. In order to assess the effect of pretreat-
ent unloading therapy on surgical outcome, in the 1980s
nd during the first half of the 1990s, the policy of the
Valve Heart Disease Unit” of our University randomly
ssigned asymptomatic patients with AR and normal LVEF
o nifedipine unloading therapy or no medical treatment. In
oth groups of patients, no other cardioactive drugs were
dministered. At the moment of randomization to nifedi-
ine or no medication, the age was comparable in the two
tudy groups (42  16 years vs. 43  18 years, p  NS).
atients were followed up with a return visit and echocar-
iographic and color Doppler evaluations every six months.
hey were enrolled into the present study at the moment of
he first appearance of reduced LVEF and then operated on
ithin three months. Left ventricular (LV) dysfunction was
efined as a reduced LVEF (50%) confirmed by an
chocardiographic study one month later. Moderately severe
grade III/IV) or severe (grade IV/IV) AR was diagnosed
ith color flow Doppler echocardiography (17). Exclusion
riteria were the following: recent development or worsen-
ng of AR (within the preceding six months), diastolic blood
ressure above 90 mm Hg, significant (50% diameter
eduction) stenosis of coronary vessels demonstrated by
Abbreviations and Acronyms
AR  chronic, severe aortic regurgitation
AVR  aortic valve replacement
LV  left ventricle/ventricular
LVEDVI  left ventricular end-diastolic volume index
LVEF  left ventricular ejection fraction
LVESVI  left ventricular end-systolic volume indexoronary angiography, mixed aortic stenosis and regurgita- eion (mean valve gradient 20 mm Hg), and evidence of
dditional valvular or congenital heart disease.
The events and cause of death were established by a
eview of medical, coroner, and autopsy records and death
ertificates. To avoid biases due to concomitant diseases able
o influence survival, associated co-morbid conditions were
ummated as a co-morbidity index (18). Informed consent
as obtained in all patients, and the study was approved by
he ethical committee of our institution.
chocardiographic analysis. Two-dimensional echocar-
iograms were recorded with a Hewlett-Packard (Andover,
assachusetts) ultrasonoscope (Sonos 2500, 4500, or 5500)
nd a 2.5- or 3.5-MHz or S3 transducer. Left ventricular
chocardiograms in the apical four-chamber and parasternal
hort-axis views in at least three to five cardiac cycles were
igitized at end diastole (peak of the R-wave) and at end
ystole (time when the cavity area was smallest). Each
chocardiogram was read by two independent observers who
id not know the patient’s identity. If the readings differed
y 10 ml or more for LV volume, data were analyzed by a
hird observer. Agreement was achieved by consensus. The
egree of interobserver and intraobserver correlation for LV
rea (r 0.98 and r 0.97, respectively) and for LV length
r  0.98 and r  0.96, respectively) was reasonable.
The LV volumes were calculated by an ellipsoid biplane
rea-length method (19); LVEF was calculated as:
LVEDVI  LVESVI)/LVEDVI, where LVEDVI is left
entricular end-diastolic volume index and LVESVI is the
eft ventricular end-systolic volume index.
Aortic regurgitation was quantified in all patients by
apping of the regurgitant jet into the LV by color Doppler
maging. The severity of regurgitation was graded with use
f the ratio of the height of the jet to that of LV outflow
ract. The height of the regurgitant jet was measured at its
rigin, immediately beneath the aortic valve, in the paraster-
al long-axis view. Ratios 45% were categorized as indi-
ating grade III/IV AR, and those 65% as grade IV/IV
R (17).
Echocardiographic study was repeated at the time of valve
eplacement, two months thereafter, and every year during
ollow-up.
tatistical analysis. All data are expressed as the mean
alue  SD. Comparisons of continuous variables in the
wo groups were made by repeated measures analysis of
ariance. Within each group, we compared preoperative and
ostoperative values by means of the paired t test. Long-
erm survival analysis was carried out using the Kaplan-
eier method, and the two-tailed k-sample log-rank test
as used to compare groups. The one-sample log-rank test
as used to compare survival with expected survival of the
ge- and gender-matched 1990s Italian census sample.
enerally, the census data do not truly constitute a relevant
atched control group, allowing a specific conclusion. To
inimize the limits of this approach, we followed this
esign: background mortality and excess mortality were
stimated from life-table data (Central Bureau for Statistics)
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April 5, 2005:1025–30 Survival After AVRontemporary to study population recruitment. Life-tables
ere compiled from the total population stratified by
ender, three-year age group, and two-year calendar period;
or each period that each patient was observed, mortality
as calculated for the same period of the counterpart from
he general population (matched with the patient for age,
ender, and year of observation). By this method, whenever
patient was lost to follow-up, we withdrew his or her
eferent from the reference group. This rate adjustment
rocedure minimizes a lack of comparability at all times to
he patient’s group. A p value 0.05 by the two-tailed test
as considered to indicate statistical significance.
ESULTS
aseline characteristics. The clinical preoperative charac-
eristics of the 266 patients who met the inclusion criteria
re listed in Table 1. Patients were seen at the University of
adua, Italy, and at the moment of diagnosis, 134 patients
group A) had been randomly assigned to treatment with
ifedipine and 132 to receive no medications (group B). All
atients underwent AVR within three months of the
ppearance of reduced LVEF. The average duration of
resurgical nifedipine therapy was 7.8 years. All patients in
roup A received nifedipine 20 mg twice daily.
Two patients in group A and two patients in group B
ere excluded from analysis because they did not return for
he scheduled follow-up visits. Thus, the long-term analysis
as performed in the remaining 262 patients (132 of group
and 130 of group B). The presumed cause of AR was
heumatic in 147 patients, degenerative in 67 patients,
ndocarditis in 14 patients, aortic valve prolapse in 8
atients, and bicuspid aortic valve in 26 patients, without
ignificant differences between groups (Table 1). Although
ge was similar at drug treatment randomization in groups
and B, by the time of operation, patients in group A were
ignificantly older, and the duration of disease was longer.
ender, comorbidity index, cardiothoracic ratio, systolic
nd diastolic blood pressure, and aortic root diameter were
imilar in the two study groups.
ortic valve replacement. All patients received a mechani-
al prosthesis. The overall operative mortality rate was 0.76%
2 of 262 patients). The operative mortality rate was similar in
he two study groups: 0.75% (1 of 132 patients) for group A
nd 0.76% (1 of 130 patients) for group B (p  NS).
Two patients in group A (after 62 and 68 months) and
wo in group B (after 64 and 65 months) required re-
peration. Operative deaths did not occur in these patients.
Survival at five years was similar in the two study groups:
4 2% for group A and 93 3% for group B patients (p
S). In group A, these values were not different from expected
94  4%), whereas in group B, five-year survival was worse
han expected (95  6%). At 10-year follow up, group A
urvival was not different from expected (group A: 85  4%,
xpected 84  5%) and significantly higher than group B (78 (5%, p  0.001), which showed a worse survival than
xpected (88  8%) (Fig. 1).
hanges in LV dimension and function after AVR.
roup A and B patients had similar preoperative values of
VEDVI, LVESVI, and LVEF (Table 1). Changes in
VEF are shown in Figure 2. After AVR, LVEF increased
ignificantly in both groups: from 46  2% to 64  8%
p  0.001) in group A and from 45  3% to 59  9%
p  0.001) in group B. After the procedure, LVEF was
igher in group A patients (p  0.001). In all nifedipine
roup patients (group A), LVEF returned to normal after
VR, whereas it remained abnormal in 36 patients (28%)
ho received no medication (group B) before surgery (p 
.01). At five-year (65  4% vs. 56  8%, p  0.001) and
0-year follow-up (62  5% vs. 48  4%, p  0.001),
VEF was persistently higher in group A patients.
Preoperative and follow-up values of LVEDVI are re-
orted in Figure 3. After AVR, there was a decrease in
VEDVI from 148  18 ml/m2 to 84  16 ml/m2 (p 
.001) in group A and from 149  16 ml/m2 to 96  24
l/m2 (p 0.001) in group B patients. After the procedure,
ignificantly higher values of LVEDVI were present in
atients of group B (p  0.001) and persisted at five-year
able 1. Baseline Characteristics of 262 Patients With Chronic,
evere Aortic Regurgitation at the Time of Aortic Valve
eplacement According to Study Group
Characteristics
Group A
(n  132)
Group B
(n  130) Total
ause of AR
Rheumatic 74 (56%) 73 (56%) 147 (56%)
Degenerative 34 (26%) 33 (25%) 67 (26%)
Bicuspid aortic valve 13 (10%) 13 (10%) 26 (10%)
Endocarditis 8 (6%) 6 (5%) 14 (5%)
Aortic valve prolapse 3 (2%) 5 (4%) 8 (3%)
ge (yrs) 58  14* 46  16
ender
Male 106 (80%) 108 (83%)
Female 26 (20%) 22 (17%)
ardiothoracic ratio 0.55  0.06 0.56  0.05
lood pressure (mm Hg)
Systolic 165  22 162  24
Diastolic 56  14 60  8
V measurements
End-diastolic volume
index (ml/m2)
148  18 149  16
End-systolic volume
index (ml/m2)
86  8 84  6
Ejection fraction (%) 46  2 45  3
ortic root diameter (mm) 45  4 45  6
o-morbidity index
0 104 (79%) 104 (80%)
1 20 (15%) 18 (14%)
2 4 (3%) 4 (3%)
3 2 (1.5%) 2 (1.5%)
4 2 (1.5%) 2 (1.5%)
isease duration (yrs) 36  4* 25  2
p  0.001 compared with group B. Data are presented as the number (%) of subjects
r mean value  SD.
AR  chronic, severe aortic regurgitation; LV  left ventricular.100  14 ml/m2 vs. 82  14 ml/m2, p  0.001) and
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Survival After AVR April 5, 2005:1025–300-year follow-up study (108  22 ml/m2 vs. 89  12
l/m2, p  0.001).
ISCUSSION
here is overwhelming evidence that patients with AR who
ecome symptomatic require prompt AVR. Conversely,
symptomatic patients generally have an excellent prognosis
ithout AVR, and controversies exist about the optimal
iming for surgical correction. Severe AR produces a sus-
ained overload on the LV, which compensates by a pro-
ressive increase in dimension and hypertrophy, whereas
VEF remains normal. Patients are asymptomatic for a
ong period of time. The hemodynamic and clinical history
f AR is usually characterized by the onset of LV dysfunc-
ion (reduced LVEF), symptoms, or both. Numerous in-
estigations (1–16,20–24) over the past three decades have
igure 1. Survival of patients with chronic severe aortic regurgitation after
urgery according to study group and compared with expected survival
solid triangles  group A patients; open triangles  general population
atched with group A; solid squares group B patients; open squares
eneral population matched with group B). Survival at five years is similar
n the two study groups and is not different from expected survival in group
. Ten-year survival of group A does not differ from expected and is
ignificantly higher than that in group B (p  0.001). Ten-year survival of
roup B is worse than expected.
igure 2. Changes in left ventricular ejection fraction (LVEF) after
urgical correction of chronic severe aortic regurgitation (solid triangles 
roup A patients; open triangles  group B patients). Group A and B
atients have similar preoperative values (Pre-op). The LVEF is higher inr
roup A patients after the procedure (Post-op) (p 0.001) and at five-year
p  0.001) and 10-year follow-up (p  0.001).rovided important information on the effect of reduced
VEF on the natural history of AR and the results of AVR.
evertheless, the issue of patients with AR after deteriora-
ion of LVEF continues to represent an intriguing clinical
nd pathophysiologic problem. In this setting, it is impor-
ant to address the questions of whether the risks of surgery
re too high and whether, even after successful AVR, any
mprovement in LVEF or survival can realistically be
xpected. The principle that the severity of LV dysfunction
as a marked influence on survival after AVR was estab-
ished in several publications supporting the conclusion that
atients with reduced LVEF did much more poorly regard-
ng long-term survival after AVR than those with preserved
r normal preoperative LVEF (1,2,13–23). These findings
ndicated the need for AVR before the development of
rreversible myocardial damage. However, other studies
howed that there is no reliable evidence that early AVR is
f benefit in asymptomatic patients with normal LVEF
3–5,9), and in the absence of symptoms, the chief indica-
ion is the development of reduced LVEF (5,10–12,14,15).
n important contribution has been the recent demonstra-
ion that patients with reduced LVEF have an outcome
ith conservative management characterized by an excess
ortality rate compared with expected mortality (5). The
uthors concluded that these patients should be considered
t high risk and evaluated for prompt surgical intervention.
nfortunately, this study included only a small number of
symptomatic patients with reduced LVEF who underwent
VR, and postsurgical survival for this subgroup is not
eported.
Moreover, it has been demonstrated that another factor
ble to influence the results of AVR after reduced LVEF
as been detected is constituted by the medical treatment of
atients in the years before. In a previous study (16), surgery
as indicated when reproducible evidence of reduced LVEF
eveloped. Unloading treatment with nifedipine exerted a
eneficial effect on the natural history of the disorder by
igure 3. Changes in left ventricular end-diastolic volume index
LVEDVI) after aortic valve replacement in study groups of patients with
hronic severe aortic regurgitation (solid squares group A patients; solid
riangles  group B patients). Group A and B patients have similar
reoperative (Pre-op) values. After valve replacement, LVEDVI decreases
ignificantly both in group A (p  0.001) and group B (p  0.001). After
urgery (Post-op), significantly higher values of LVEDVI are present in
roup B (p  0.001) and are still present at five-year (p  0.001) and
0-year follow-up study (p  0.001).educing the need for AVR. Of greater importance, patients
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April 5, 2005:1025–30 Survival After AVRn whom a reduced LVEF developed while they were being
reated with nifedipine all responded favorably to AVR and
ad normalized LVEF.
The results of the present study confirmed that the first
ppearance of reduced LVEF in asymptomatic patients
reated by an unloading therapy with nifedipine is not an
rreversible process. All nifedipine-treated patients operated
n at the appearance of reduced LVEF had normalized
VEF after AVR, and at 10-year follow-up, LVEF was still
ormal. In these patients, reduced LVEF presumably oc-
urred without irreversible myocardial contractile damage,
nd this mechanism may explain the favorable effects of
VR on LVEF and long-term outcome (24–26). At this
oment in the natural history of AR, the surgical procedure
estores an adequate match between myocardial contractility
nd LV load by reversing the excessive load imposed by AR.
onversely, in some patients who were not receiving med-
cation, the persistent LV damage after AVR was presum-
bly resulting from irreversible myocardial contractile dys-
unction before AVR (24,26). More generally, in these
atients not receiving unloading therapy, the presence of
yocardial dysfunction, of a different extent, may also
xplain the progressive postoperative deterioration in LVEF
ver time and the poor outcome (26,27). Thus, changes in
VEF after AVR might explain the difference in survival:
atients treated with unloading therapy before AVR had a
ignificant improvement of long-term survival in compari-
on to patients receiving no medication, who had a worse-
han-expected 10-year survival. It is important to stress that
he more advantageous results of surgery occurred despite
atients treated with nifedipine being older and the duration
f the disease longer, presumably as a result of the capacity
f this therapy to delay surgery (16).
tudy limitations. Systolic hypertension is a known risk
actor for heart failure, and the risk of systolic hypertension
n patients with AR was first demonstrated by Spagnuolo et
l. (28). In our study, patients had moderately severe systolic
ypertension at the time of operation. As a consequence, the
tudy results do not allow to us advocate the use of
ifedipine in patients with AR who are not hypertensive.
evertheless, this use could possibly be reasonable and
ppropriate because afterload reduction in AR by nifedipine
oes not require systolic hypertension.
More than half of our patients in both groups had a
heumatic origin of their AR, and one-quarter had a
egenerative origin. Hence, the results of this study are
uch more pertinent to this AR population and certainly
ess determinant in patient groups of AR with other causes
percentage of patients in our study: 10% with a bicuspid
ortic valve, 5% with endocarditis, and 3% with aortic valve
rolapse).
onclusions. Unloading therapy with nifedipine in
symptomatic patients with AR represents a pharmacologic
trategy capable of delaying the need for surgery by pro-
onging the asymptomatic period while preserving LVEF.
his treatment allows one to indicate AVR at the appear- 1nce of reduced LVEF with a low operative mortality and
ith significant improvement of long-term postoperative
urvival.
On the other hand, the concept of surgical correction of
R indicated for the appearance of reduced LVEF may not
e applied in all patients. In fact, in the absence of an
ppropriate unloading therapy, reduced LVEF is not re-
ersed by prompt surgery, indicating the presence of irre-
ersible myocardial damage, and the 10-year survival is
orse than expected.
eprint requests and correspondence: Dr. Roldano Scog-
amiglio, Cattedra e Divisione di Cardiologia, Policlinico Univer-
itario, via Giustiniani 2, I-35128 Padova, Italy. E-mail:
.scognamiglio@unipd.it.
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